DGCI gives emergency approval of DRDO-developed anti-Covid oral drug | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
July 14, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, JULY 14, 2025
DGCI gives emergency approval of DRDO-developed anti-Covid oral drug

Coronavirus chronicle

Hindustan Times
08 May, 2021, 02:25 pm
Last modified: 08 May, 2021, 02:28 pm

Related News

  • India showcases naval ballistic missile defence capability in maiden test
  • Beximco to produce Pfizer’s Covid-19 drug locally 
  • Beximco Pharma gets license for oral anti-Covid drug
  • Incepta launches Pfizer’s anti-Covid pill
  • WHO-led program aims to buy antiviral Covid-19 pills for $10

DGCI gives emergency approval of DRDO-developed anti-Covid oral drug

The oral drug has been developed by Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. Phase III clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence

Hindustan Times
08 May, 2021, 02:25 pm
Last modified: 08 May, 2021, 02:28 pm
Indian Prime Minister Narendra Modi. Photo: NDTV
Indian Prime Minister Narendra Modi. Photo: NDTV

An anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy's Laboratories, Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. The drug will be of immense benefit to the people suffering from Covid in the ongoing pandemic.

Pursuing the Hon'ble Prime Minister's call for preparedness against the pandemic, DRDO took the initiative of developing anti-Covid therapeutic application of 2-DG. In April 2020, during the first wave of pandemic INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India's (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in Covid-19 patients in May 2020.

DRDO along with its industry partner Dr Reddy's Laboratories (DRL, Hyderabad) started the clinical trials to test the safety and efficacy of the drug in Covid-19 patients. In Phase-II trials (including dose ranging) conducted during May to October 2020, the drug was found to be safe in Covid-19 patients, and showed significant improvement in their recovery. Phase IIa was conducted in 6 hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients. In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SOC.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Top News / World+Biz

DGCI / Defence Research and Development Organisation (DRDO) / Covid oral drug / oral drug

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infographic: TBS
    Govt to set six conditions to prevent delays, waste in foreign-funded projects
  • BNP Secretary General Mirza Fakhrul Islam Alamgir at a press conference held at the BNP Chairperson Khaleda Zia’s political office in Gulshan on 14 July 2025. Photo: Screengrab
    Well-orchestrated propaganda launched against BNP to prevent restoration of democratic politics: Fakhrul
  • National Consensus Commission logo. Image: Collected
    Consensus Commission begins 13th day of discussion on women's representation in parliament

MOST VIEWED

  • From Gulf to Southeast Asia, why Bangladeshis are facing visa denials
    From Gulf to Southeast Asia, why Bangladeshis are facing visa denials
  • Infographic: TBS
    Dollar price plummets by Tk2.9 in a week as demand wanes
  • Energy Adviser Fouzul Kabir Khan speaking about tariff negotiations with United States on 13 July 2025. Photo: TBS
    US wants a framework agreement with Bangladesh that includes their security concerns: Fouzul
  • CNG drivers blockaded a road in Banani demanding route allocation on 13 July 2025. Photo: TBS
    CNG drivers block road in Banani for hours, causing Mohakhali-Uttara gridlock 
  • BSEC directs 44 firms to transfer Tk1,000cr in unclaimed dividends to CMSF
    BSEC directs 44 firms to transfer Tk1,000cr in unclaimed dividends to CMSF
  • TBS Sketch
    Framework agreement: What experts say about US 'security concerns' regarding Bangladesh

Related News

  • India showcases naval ballistic missile defence capability in maiden test
  • Beximco to produce Pfizer’s Covid-19 drug locally 
  • Beximco Pharma gets license for oral anti-Covid drug
  • Incepta launches Pfizer’s anti-Covid pill
  • WHO-led program aims to buy antiviral Covid-19 pills for $10

Features

Photo: Collected

Grooming gadgets: Where sleek tools meet effortless styles

20h | Brands
The 2020 Harrier's Porsche Cayenne coupe-like rear roofline, integrated LED lighting with the Modellista special bodykit all around, and a swanky front grille scream OEM Plus for the sophisticated enthusiast looking for a bigger family car that isn’t boring. PHOTO: Ahbaar Mohammad

2020 Toyota Harrier Hybrid: The Japanese Macan

1d | Wheels
The showroom was launched through a lavish event held there, and in attendance were DHS Motors’ Managing Director Nafees Khundker, CEO Imran Zaman Khan, and GMs Arman Rashid and Farhan Samad. PHOTO: Akif Hamid

GAC inaugurate flagship showroom in Dhaka

1d | Wheels
After India's visa restriction, China's Kunming is drawing Bangladeshi patients

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

2d | Panorama

More Videos from TBS

Iranian president narrowly escapes Israeli attack

Iranian president narrowly escapes Israeli attack

1h | TBS World
Why Modhumoti Bank’s NPL ratio stays below 2.5%

Why Modhumoti Bank’s NPL ratio stays below 2.5%

2h | TBS Programs
'Boat' to remain in symbol list, 'Shapla' not included: EC Machud

'Boat' to remain in symbol list, 'Shapla' not included: EC Machud

3h | TBS Today
When the Threat Is Inside the White House

When the Threat Is Inside the White House

15h | Others
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net